Ajaratu Keshinro1, Chad Vanderbilt2, Jin K Kim1, Canan Firat2, Chin-Tung Chen1, Rona Yaeger3, Karuna Ganesh3,4, Neil H Segal3, Mithat Gonen5, Jinru Shia2, Zsofia Stadler3, Martin R Weiser1. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
To characterize the relationship between tumor-infiltrating lymphocytes (TIL), tumor mutational burden (TMB), and genetic alterations in microsatellite stable (MSS), microsatellite instability (MSI), or mutant POLE/POLD1 colon cancer. MATERIALS AND METHODS: Four hundred ninety-nine resected stage I-III colon tumors treated between 2014 and 2019 were assessed for TIL; somatic mutations, copy number alterations, and structural changes in > 400 oncogenes; and MSI status. RESULTS: Of the 499 tumors analyzed, 313 were MSS, 175 were MSI, and 11 had POLE/POLD1 pathogenic mutations. Both the percentage of tumors with a high level of TIL (≥ 4 lymphocytes per high-power field) and the median TMB differed significantly between the three phenotypes: MSS, 4.5% and 6 mutations/Mb; MSI, 68% and 54 mutations/Mb; POLE/POLD1, 82% and 158 mutations/Mb (P < .05). Within each phenotype, TMB did not vary significantly with TIL level. Among MSI tumors, the median number of frameshift indels was significantly higher in tumors with high levels of TIL (20 v 17; P = .018). In the MSS group, significantly higher proportions of tumors with high levels of TIL had mutations in the transforming growth factor-β (36% v 12%; P = .01), RAS (86% v 54%; P = .02), and Hippo (7% v 1%; P = .046) pathways; in contrast, TP53 alterations were associated with low levels of TIL (74% v 43%; P = .01). CONCLUSION: The association between TIL, TMB, and genetic alterations varies significantly between MSI, MSS, and mutant POLE/POLD1 colon tumors. These differences may help explain tumoral immunity and lead to predictors of response to immunotherapy.
To characterize the relationship between tumor-infiltrating lymphocytes (TIL), tumor mutational burden (TMB), and genetic alterations in microsatellite stable (MSS), microsatellite instability (MSI), or mutant POLE/POLD1 colon cancer. MATERIALS AND METHODS: Four hundred ninety-nine resected stage I-III colon tumors treated between 2014 and 2019 were assessed for TIL; somatic mutations, copy number alterations, and structural changes in > 400 oncogenes; and MSI status. RESULTS: Of the 499 tumors analyzed, 313 were MSS, 175 were MSI, and 11 had POLE/POLD1 pathogenic mutations. Both the percentage of tumors with a high level of TIL (≥ 4 lymphocytes per high-power field) and the median TMB differed significantly between the three phenotypes: MSS, 4.5% and 6 mutations/Mb; MSI, 68% and 54 mutations/Mb; POLE/POLD1, 82% and 158 mutations/Mb (P < .05). Within each phenotype, TMB did not vary significantly with TIL level. Among MSI tumors, the median number of frameshift indels was significantly higher in tumors with high levels of TIL (20 v 17; P = .018). In the MSS group, significantly higher proportions of tumors with high levels of TIL had mutations in the transforming growth factor-β (36% v 12%; P = .01), RAS (86% v 54%; P = .02), and Hippo (7% v 1%; P = .046) pathways; in contrast, TP53 alterations were associated with low levels of TIL (74% v 43%; P = .01). CONCLUSION: The association between TIL, TMB, and genetic alterations varies significantly between MSI, MSS, and mutant POLE/POLD1 colon tumors. These differences may help explain tumoral immunity and lead to predictors of response to immunotherapy.
Authors: S I Abrams; S N Khleif; E S Bergmann-Leitner; J A Kantor; Y Chung; J M Hamilton; J Schlom Journal: Cell Immunol Date: 1997-12-15 Impact factor: 4.868
Authors: Xaralabos Varelas; Bryan W Miller; Richelle Sopko; Siyuan Song; Alex Gregorieff; Frederic A Fellouse; Rui Sakuma; Tony Pawson; Walter Hunziker; Helen McNeill; Jeffrey L Wrana; Liliana Attisano Journal: Dev Cell Date: 2010-04-20 Impact factor: 12.270
Authors: David Tougeron; Emilie Fauquembergue; Alexandre Rouquette; Florence Le Pessot; Richard Sesboüé; Michèle Laurent; Pascaline Berthet; Jacques Mauillon; Frédéric Di Fiore; Jean-Christophe Sabourin; Pierre Michel; Mario Tosi; Thierry Frébourg; Jean-Baptiste Latouche Journal: Mod Pathol Date: 2009-06-05 Impact factor: 7.842
Authors: Isaac Wasserman; Lik Hang Lee; J Joshua Smith; Shuji Ogino; Michael R Marco; Chao Wu; Xi Chen; Jashodeep Datta; Eran Sadot; Bryan Szeglin; Jose G Guillem; Philip B Paty; Martin R Weiser; Garrett M Nash; Leonard Saltz; Afsar Barlas; Katia Manova-Todorova; Srijaya Prakash Babu Uppada; Arthur E Elghouayel; Peter Ntiamoah; Jonathan N Glickman; Tsuyoshi Hamada; Keisuke Kosumi; Kentaro Inamura; Andrew T Chan; Reiko Nishihara; Andrea Cercek; Karuna Ganesh; Nancy E Kemeny; Punita Dhawan; Rona Yaeger; Charles L Sawyers; Julio Garcia-Aguilar; Marios Giannakis; Jinru Shia Journal: Clin Cancer Res Date: 2018-12-26 Impact factor: 12.531
Authors: Alicia C Smart; Claire A Margolis; Harold Pimentel; Meng Xiao He; Diana Miao; Dennis Adeegbe; Tim Fugmann; Kwok-Kin Wong; Eliezer M Van Allen Journal: Nat Biotechnol Date: 2018-08-16 Impact factor: 54.908
Authors: Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles Journal: Nature Date: 2018-02-14 Impact factor: 49.962
Authors: Jin K Kim; Chin-Tung Chen; Ajaratu Keshinro; Asama Khan; Canan Firat; Chad Vanderbilt; Neil Segal; Zsofia Stadler; Jinru Shia; Vinod P Balachandran; Martin R Weiser Journal: Oncoimmunology Date: 2022-04-14 Impact factor: 7.723
Authors: Benjamin Garmezy; Jinesh Gheeya; Heather Y Lin; Yuefan Huang; Taebeom Kim; Xianli Jiang; Kyaw Z Thein; Patrick G Pilié; Fadl Zeineddine; Wanlin Wang; Kenna R Shaw; Jordi Rodon; John Paul Shen; Ying Yuan; Funda Meric-Bernstam; Ken Chen; Timothy A Yap Journal: JCO Precis Oncol Date: 2022-02